European commission approves keytruda® (pembrolizumab) as part of a treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma (la-hnscc) expressing pd-l1 (cps >1)

Rahway, n.j.--(business wire)---- $mrk #mrk--merck (nyse: mrk), known as msd outside of the united states and canada, today announced that the european commission (ec) has approved keytruda® (pembrolizumab), merck's anti-pd-1 therapy, as monotherapy for the treatment of resectable locally advanced head and neck squamous cell carcinoma (la-hnscc) as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adul.
CPSH Ratings Summary
CPSH Quant Ranking